
Link explored between GLP-1 weight loss drugs and rare brain condition
A rare brain disorder called Wernicke encephalopathy has been identified in a small number of people taking GLP-1 weight-loss and diabetes drugs. An Israeli review of FDA adverse-event reports and medical literature found about 15 cases (mostly in patients with GI side effects and malnutrition). While the study suggests a possible link, causation isn’t proven and patients shouldn’t stop medication; emergency thiamine treatment is essential if Wernicke is suspected, and more research is needed to clarify risk.












